NEW YORK (GenomeWeb News) – Shares of CombiMatrix were up 20 percent in Thursday afternoon trade after the firm put out a statement pointing to a new recommendation from the American College of Obstetricians and Gynecologists that chromosomal microarray analysis should be the first-line genetic test in pregnancies where ultrasound screens uncover signs of fetal abnormalities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.